Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology

Core Insights - A study by Myriad Genetics demonstrated that the use of an online screening tool and patient education significantly increased the completion rate of hereditary cancer testing among patients [1][2][8] Group 1: Study Findings - The implementation of MyGeneHistory, an online patient screening tool, led to a 30% increase in the identification of patients meeting guidelines for hereditary cancer testing (HCT) [8] - There was a 50% increase in the number of patients who met the guidelines and were offered HCT [8] - More than twice the number of patients completed HCT after the introduction of the online tool and education program [8] Group 2: Clinical Impact - Clinicians reported increased confidence in administering hereditary cancer risk assessments, with 87% stating that the online tools helped them adhere to recommended standards of care [3] - Over 80% of providers believed the program assisted them in following ACOG guidelines for hereditary cancer risk assessment [3] Group 3: Program Details - Myriad's Breast Cancer Risk Assessment Program includes the MyRisk with RiskScore Hereditary Cancer Test and the MyGeneHistory online screening tool, which assesses if a patient meets medical guidelines for hereditary cancer testing [5] - The program also provides patient education on genetic testing and guidance on collecting family history related to certain cancers [5] Group 4: Study Overview - The study involved over 10,000 patients across five U.S. community obstetrics/gynecology practices, with an eight-week observation period followed by training on the online screening and education program [6]